NCT02460146已完成1 期
A Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Sequential Multiple Ascending, Repeat Doses of Oral CXA-10 in Healthy Obese Male Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 43
- 试验地点
- 1
- 主要终点
- Safety (adverse events) and tolerability of multiple ascending oral doses of CXA 10 administered daily for 14 days
研究概览
简要总结
The main purpose of this trial is to demonstrate the safety, tolerability and pharmacokinetics (PK) of CXA-10 and its metabolite(s) administered as multiple ascending oral doses over 14 days to healthy obese male volunteers.
详细描述
Complexa has developed an oral formulation of CXA-10. The main purpose of this trial is to demonstrate the safety, tolerability and pharmacokinetics (PK) of CXA-10 and its metabolite(s) administered as multiple ascending oral doses over 14 days to healthy obese male volunteers. The pharmacodynamic (PD) effects of CXA-10 on serum biomarkers, some of which are elevated in the obese population, will also be investigated.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Body mass index (BMI) >27 and ≤40 kg/m2
- •In good general health as determined by a thorough medical history and physical examination, ECG, vital signs, and clinical laboratory evaluation
- •Results of clinical laboratory tests must be without clinically significant abnormalities for this population and may exceed the limits of the reference ranges, including hematology, clinical chemistry and urinalysis except as noted below
- •Hemoglobin A1c (HbA1c) <7%
- •Average blood pressure <160/100 mmHg at screening
- •QTcF interval (Fredericia's correction factor) must be ≤430 msec at screening and pre-dose
排除标准
- •Any clinically relevant abnormality for this population identified on the screening history, physical or laboratory examinations, or any other medical condition or circumstance making the volunteer unsuitable for participation in the study
- •Any clinical history of cardiovascular events, arrhythmias, fainting, palpitations, personal or family history of congenital prolonged QT syndromes or sudden unexpected death due to a cardiac reason
- •History of any primary malignancy, including a history of melanoma or suspicious undiagnosed skin lesions, with the exception of basal cell or squamous cell carcinomas of the skin or cervical carcinoma in situ or other malignancies curatively treated and with no evidence of disease for at least 5 years
- •History of regular alcohol consumption exceeding 21 units/week (one unit = 125 mL of wine or 284 mL of beer or a single 25 mL measure of spirits) within 6 months of screening
- •Treatment with any prescription or non-prescription drugs (including vitamins, herbal and dietary supplements) within 7 days or 5 half-lives, whichever is longer, prior to dosing and until collection of the final PK sample. Use of any drug including aspirin or non-steroidal anti-inflammatory drugs (NSAIDs) must be avoided within 7 days prior to the first dose and during this study as it may interfere with the pharmacology of CXA-
- •Use of high energy supplements or drinks (especially, those containing caffeine, protein supplements, and weight loss drugs)
- •History of smoking, including e-cigarettes, or use of nicotine-containing products within 1 month of screening
- •Resting heart rate ≥100 BPM after 5 minutes rest (as above) at the screening visit
- •Subjects with any other clinically relevant ECG parameter abnormality (e.g., PR interval, QRS deviation) or any clinically significant ECG abnormality will be excluded from the study
- •Any clinically significant murmurs evident on auscultation of the heart (including evidence of mitral valve prolapse)
研究组 & 干预措施
CXA-10
Active Comparator
CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitrated oleic acid
干预措施: CXA-10 (Drug)
CXA-10 placebo
Placebo Comparator
The placebo contains olive oil with BHT (0.08% to 0.10%).
干预措施: CXA-10 placebo (Other)
结局指标
主要结局
Safety (adverse events) and tolerability of multiple ascending oral doses of CXA 10 administered daily for 14 days
时间窗: 14 days
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-64264681 in Healthy Male and Female ParticipantsHealthyNCT03607513Janssen Research & Development, LLC105
Unknown
1 期
Phase Ⅰ Clinical Study Protocol of GB223 Monoclonal Antibody InjectionBone TumorNCT04178044Genor Biopharma Co., Ltd.44
已完成
1 期
IAMA-6 Oral Dose Study in Healthy AdultsNeurodevelopmental DisordersNCT06300398Iama Therapeutics S.r.l.72
已完成
1 期
A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of Oral HMS5552 in Healthy VolunteersType II Diabetes MellitusNCT01952535Hua Medicine Limited60
已完成
1 期
A Phase 1 Study of Y-3 in US Healthy Volunteers.SafetyTolerabilityPharmacokinetic Study in Healthy VolunteersNCT06770491Neurodawn Pharmaceutical Co., Ltd.20